Roxana R. C.
- Country
- Spain
- Department
- Medical Oncology – IOB Institute of Oncology
Research Overview
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
- Phase 2 Study Evaluating Safety and Tolerability of Alisertib Combined with Paclitaxel in Patients with Small Cell Lung Cancer
- Phase 2b Multicenter Trial Evaluating Zipalertinib in Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion and Uncommon/Compound Mutations
Data & Insights
Has run more than one trial at 68 of 198 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in treating advanced and metastatic non-small cell lung cancer (NSCLC), with particular emphasis on innovative therapeutic combinations.
- Advanced Stage Lung Cancer Treatment
- Metastatic NSCLC Management
- Combination Therapy Approaches
The investigator focuses on evaluating treatment efficacy in PD-L1 unselected populations, exploring new therapeutic pathways for lung cancer patients.
Immunotherapy Research
The investigator's work centers on immunotherapeutic approaches in oncology, particularly studying novel immunotherapy agents in combination with established treatments.
- Immune Checkpoint Inhibition
- Combination Immunotherapy
- Novel Immunologic Agents
Their research explores the integration of immunotherapy with conventional chemotherapy protocols for enhanced treatment outcomes.
Therapeutic Innovation
The investigator evaluates novel therapeutic combinations for advanced cancer treatment, focusing on integrating new compounds with established treatment protocols.
- Innovative Drug Development
- Treatment Protocol Optimization
- Clinical Efficacy Assessment
Their work includes studying the effectiveness of combined treatment modalities in advanced cancer care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.